Disulfide Constrained Peptides for Targeting the Prostate Specific Membrane Antigen

Case ID:
C04111
Disclosure Date:
7/26/2002
Description:
C04111: Disulfide Constrained Peptides for Targeting the Prostate Specific Membrane Antigen
Technical Details:
Utilizing a standard phage display methodology, we have screened a hepta-peptide disulfide bridge constrained phage display library for binding to the prostate specific membrane antigen (PSMA). PSMA is a prostate specific cell surface marker which is up regulated in aggressive prostate cancer and is considered one of the best cell surface targets for prostate cancer currently available. A variety of peptide ligands were generated and found to bind to PSMA with varying affinities. At least one of the ligands appears to have extremely high binding affinity (in the 100 nM range).
Looking for Partners:
Non-viral gene transfer Viral gene transfer Targeted diagnostics (i.e., imaging of metastatic prostate cancer cells) Targeted therapeutics (i.e., systemic treatment of metastatic prostate cancer cells). Such therapeutics could include radiopharmaceuticals, chemotherapeutics, immunotoxins, biologic agents, gene transfer.
Patent Information:
Inventors:
Category(s):
For Information, Contact:
Vera Sampels
vsampel2@jhu.edu
410-614-0300
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum